Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Venous Leg Ulcers (Crural Ulcer) - Overview
Venous Leg Ulcers (Crural Ulcer) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Venous Leg Ulcers (Crural Ulcer) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Venous Leg Ulcers (Crural Ulcer) - Companies Involved in Therapeutics Development
CardioVascular BioTherapeutics Inc
CytoTools AG
FirstString Research Inc
GangaGen Inc
Mallinckrodt Plc
MediWound Ltd
NovaLead Pharma Pvt Ltd
Promore Pharma AB
Venous Leg Ulcers (Crural Ulcer) - Drug Profiles
AUP-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVBT-141B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diperoxochloric acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBC-1013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EscharEx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EscharEx Second Generation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LL-37 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLP-328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-42909 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products
Venous Leg Ulcers (Crural Ulcer) - Product Development Milestones
Featured News & Press Releases
Aug 27, 2019: Promore Pharma is granted a patent for LL-37 in Japan
Jul 22, 2019: MediWound launches EscharEx U.S. clinical development program
Jun 20, 2019: Promore Pharma has recruited half of the patients in HEAL LL-37
Oct 01, 2018: Promore Pharma has enrolled first patient in HEAL LL-37 in Poland
Sep 06, 2018: Promore Pharma has conducted Investigator Meeting for HEAL LL-37 in Poland
Aug 22, 2018: Promore Pharma receives approval for Phase IIb trial with LL-37 in Poland
Jul 03, 2018: Promore Pharma receives approval for Phase IIb trial with LL-37
Oct 31, 2017: Promore Pharma Signs Agreement with CRO PCG Clinical Services
Sep 21, 2017: Promore Pharma Signs Manufacturing Agreement with APL
Sep 12, 2017: Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days
Sep 01, 2017: MediWound Successfully Completes Second Cohort of EscharEx Phase 2 Study
Jun 20, 2017: FirstString’s President and CEO, Dr. Gautam Ghatnekar, Presents at the 2017 BIO Intertiol Convention in San Diego, CA
Jan 18, 2017: FirstString Research Wins Prestigious Tibbetts Award
Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results
Oct 10, 2013: Pergamum announces fil data from Phase I/II study of LL-37 in patients with chronic leg ulcers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Venous Leg Ulcers (Crural Ulcer), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by CardioVascular BioTherapeutics Inc, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by CytoTools AG, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by FirstString Research Inc, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by GangaGen Inc, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Mallinckrodt Plc, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by MediWound Ltd, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by NovaLead Pharma Pvt Ltd, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Pipeline by Promore Pharma AB, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Dormant Projects, H2 2019
Venous Leg Ulcers (Crural Ulcer) - Discontinued Products, H2 2019